Skip to main content
Breast Cancer
A Subanalysis of the Phase 3 MONARCH 3 Study of Abemaciclib as Initial Therapy for HR-Positive, HER2-Negative Advanced Breast Cancer
Read More
Breast Cancer
Effectiveness of Alpelisib plus Fulvestrant Compared with Real-World Standard Treatment Among Patients with HR-Positive, HER2-Negative, PIK3CA Mutation–Positive Breast Cancer
Read More
Breast Cancer
Updates on Endocrine Therapy for Metastatic Breast Cancer
Read More
Breast Cancer
Patient-Reported Outcomes from a Phase 3 Trial in Premenopausal Patients with ER-Positive, HER2-Negative, Lymph Node–Positive Breast Cancer
Read More
Breast Cancer
Checkpoint Inhibitor Therapy for Metastatic Triple-Negative Breast Cancer
Read More
Breast Cancer, Antibody–Drug Conjugates
Emerging Immunotherapy Combination Strategies for Breast Cancer: Dual Immune Checkpoint Modulation, Antibody–Drug Conjugates, and Bispecific Antibodies
Read More
Breast Cancer
Sacituzumab Govitecan for Metastatic Triple-Negative Breast Cancer: An Overview of Clinical Management and Potential Toxicities
Read More
Breast Cancer
SASCIA Phase 3 Trial Evaluating Sacituzumab Govitecan in Patients with Primary HER2-Negative Breast Cancer with High Relapse Risk
Read More
Breast Cancer
Trastuzumab Deruxtecan Granted Breakthrough Therapy Designation in United States for Patients with HER2-Positive Metastatic Breast Cancer Treated with ≥1 Previous Anti-HER2–Based Regimens
Read More
Breast Cancer, Antibody–Drug Conjugates
New Antibody–Drug Conjugates in Breast Cancer
Read More
Page 1 of 3
Results 1 - 10 of 28